AVENIO ctDNA Surveillance Kit V2
Optimized tumor burden monitoring in lung and colorectal cancer research
The AVENIO ctDNA Surveillance Kit is a next-generation sequencing (NGS) liquid biopsy research use only assay that’s specially designed and optimized for longitudinal tumor burden monitoring in lung cancer and colorectal cancer (CRC) research. The Surveillance panel contains 197 genes, including those in the US National Comprehensive Cancer Network (NCCN) Guidelines.1
AVENIO ctDNA Surveillance Kit V2 analytical performance3
View full tableAVENIO ctDNA Surveillance Kit V2 analytical performance3
Mutation class |
SNVs |
Indels |
Fusions |
CNVs** |
|||
| Mutant allele frequency/copy number | 0.5%* | 1.0%* | 1.0% | Sample dependent
|
|||
|---|---|---|---|---|---|---|---|
| Sensitivity and PPV | Sensitivity | PPV | Sensitivity | PPV | Sensitivity | PPV | |
| >99% | >95% | >99% | >99% | >99% | >99% | ||
**The kit reports ERBB2, EGFR, and MET CNVs. Performance is dependent on various factors, including sample type, input DNA amount, percent tumor content, and the individual tumor's genomic copy number. Our technical study detected CNVs at dPCR-verified copy numbers, using a commercially available reference sample (50ng). CNV specificity was high (PPV >99%). ERBB2 detected at 4.5 copies, MET detected at 4.5 copies.
Performance samples: Seraseq ctDNA Complete Mutation Mixes (SeraCare), healthy donor cfDNA.
Sensitivity and Positive Predictive Value (PPV) metrics based on observed product performance. Sensitivity and PPV performance reported per variant. Sensitivity was determined using commercially available reference samples containing verified mutations at the stated allele frequencies. SNV performance data based on hotspot calls. The AVENIO ctDNA Analysis Kit V2 can achieve >99.99% per base specificity across each of the panels. Stated performance requires at least 40 million reads per sample for all AVENIO ctDNA Panels V2. Sequencing performed on an Illumina NextSeq 500/550/550Dx (Research Use Only mode) instrument.
AVENIO ctDNA Surveillance Kit V2 specifications
View full tableAVENIO ctDNA Surveillance Kit V2 specifications
Product specifications |
Value |
Panel size |
198 kb |
Sample size |
4 ml of plasma |
cfDNA input |
10-50 ng |
Reactions per kit |
16 |
Turn-around time |
5 days from extraction to results |
Use left and right arrow keys to scroll between the tabs
Key product features
NCCN guideline genes: The assay includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines.1
All mutation classes: All four mutation classes (SNVs, indels, fusions, and CNVs) are included in one assay.
Comprehensive package: The assay is inclusive of reagents, bioinformatics, and software.
AVENIO assays are for Research Use Only. Not for use in diagnostic procedures.
References
- National Comprehensive Cancer Network [Internet; cited 2025 Nov 20]. Available from: https://www.nccn.org/
- Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Med. 2014;20(5):548–554 doi:10.1038/nm.3519. Available from: https://www.nature.com/articles/nm.3519
- F. Hoffmann-La Roche Ltd. Data on file.